[Extrapulmonary tuberculosis: case of a 70-year-old woman suffering from cutaneous lymph node, renal and bone tuberculosis ].

We have described a case of a 70-year-old woman, treated for a pancreas cancer, which was diagnosed for many months because of atypical skin lesions, lymphadenopathy and progressing cachexia. Despite many autoimmunological, serological, histopathological, bacteriological and mycological examinations there was no diagnosis. Finally the case of extrapulmonary tuberculosis involving skin, lymph nodes, kidneys and bones was diagnosed.

Synthesis and in vitro tuberculostatic activity of Co (II), Cu (II) and Ni (II) complexes of dialdehyde starch dithiosemicarbazone.

Co (II), Cu (II) and Ni (II) complexes of starch dialdehyde dithiosemicarbazone (DASTSC) of low (approximately 15%) degree of oxidation were prepared and their tuberculostatic activity was tested in vitro against isoniazid-sensitive and isoniazid-resistant strains of Mycobacterium tuberculosis. In 10-week lasting tests the DASTSC complex with Ni (II) was tuberculostatic to a similar extent as was the free ligand, whereas the Co (II) and Cu (II) complexes inhibited the growth of M. tuberculosis more efficiently.

Antimicrobial activity of starch dialdehyde dithiosemicarbazone against Mycobacterium tuberculosis.

A dithiosemicarbazone of 13% starch dialdehyde (DASTSC) was active against Mycobacterium tuberculosis under laboratory tests. M. tuberculosis strains sensitive and resistant to isoniazid (INH) were developed at the concentrations of 2.

[Treatment of respiratory tract infections with pefloxacin].

Pefloxacin, a 4-quinolone derivative, was administered in the dose of 800-1200 mg for the mean of 12 days to 24 patients with respiratory tract infection complicating chronic bronchial asthma or chronic obstructive lung disease. Patients with positive sputum culture and bacteria sensitive to pefloxacin were included in the study. Total eradication of the offending microorganisms was achieved in 54% of patients, and partial--in the next 20%.